Tofacitinib for Prurigo Nodularis: A Case Report

PURPOSE: Despite recent advances in the treatment of prurigo nodularis, conventional treatment suffers from a dilemma of poor efficacy. The clinical use of Janus kinase (JAK) inhibitors in the treatment of Prurigo nodularis has rarely been explored. PATIENTS AND METHODS: We present a case of prurigo nodularis successfully treated with, JAK inhibitor tofacitinib with no adverse effects. RESULTS: This case report of successful treatment shows a good clinical efficacy of using JAK inhibitor tofacitinib in the treatment of prurigo nodularis. Cytokines may be an important cause of prurigo nodularis. CONCLUSION: JAK inhibitor tofacitinib may be a new option for the treatment of prurigo nodularis, especially for patients who have failed conventional treatment.